Skip to main content
Journal cover image

Oral Versus Intravenous Antibiotic Therapy for Staphylococcus aureus Bacteremia or Endocarditis: A Systematic Review and Meta-Analysis of Randomized, Controlled Trials.

Publication ,  Journal Article
Mourad, A; Nwafo, N; Skalla, L; Holland, TL; Jenkins, TC
Published in: Clin Infect Dis
February 5, 2025

BACKGROUND: We conducted a systematic review of randomized, controlled trials (RCTs) to generate more precise estimates of the efficacy and safety of oral versus intravenous antibiotic therapy for Staphylococcus aureus bacteremia or endocarditis. METHODS: MEDLINE, Embase, the Cochrane Library, and Web of Science databases were searched through February 2024. RCTs were included if they compared oral versus intravenous antibiotic therapy for S. aureus bacteremia or endocarditis and appropriately reported outcomes for each group. Risk of bias was assessed using the revised Cochrane tool for assessing risk of bias in randomized trials. Heterogeneity between studies was evaluated with Cochran's Q-statistic and I2 test. Treatment effects were summarized with pooled risk ratios using a random effects model meta-analysis (PROSPERO CRD42024481512). RESULTS: Only four RCTs met criteria for inclusion in meta-analysis. Among participants assessed for treatment failure, there was no difference between oral and intravenous therapy groups (risk ratio [RR], 0.99; 95% confidence interval [CI], .63-1.57; I2 = 0%). There was also no significant difference in adverse events between oral and intravenous therapy groups (RR, 0.65; 95% CI, .07-5.94; I2 = 74%); however, the confidence interval was wide, and heterogeneity was high. CONCLUSIONS: In this systematic review of RCTs comparing oral with intravenous antibiotic therapy for S. aureus bacteremia or endocarditis, few studies met the eligibility criteria for inclusion. Meta-analysis of these studies suggests that transitioning from intravenous to oral therapy is likely effective in a subgroup of carefully selected patients. Additional randomized trials are necessary before transition to oral therapy can be routinely recommended.

Duke Scholars

Published In

Clin Infect Dis

DOI

EISSN

1537-6591

Publication Date

February 5, 2025

Volume

80

Issue

1

Start / End Page

29 / 36

Location

United States

Related Subject Headings

  • Treatment Outcome
  • Staphylococcus aureus
  • Staphylococcal Infections
  • Randomized Controlled Trials as Topic
  • Microbiology
  • Humans
  • Endocarditis, Bacterial
  • Bacteremia
  • Anti-Bacterial Agents
  • Administration, Oral
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Mourad, A., Nwafo, N., Skalla, L., Holland, T. L., & Jenkins, T. C. (2025). Oral Versus Intravenous Antibiotic Therapy for Staphylococcus aureus Bacteremia or Endocarditis: A Systematic Review and Meta-Analysis of Randomized, Controlled Trials. Clin Infect Dis, 80(1), 29–36. https://doi.org/10.1093/cid/ciae476
Mourad, Ahmad, Nnamdi Nwafo, Lesley Skalla, Thomas L. Holland, and Timothy C. Jenkins. “Oral Versus Intravenous Antibiotic Therapy for Staphylococcus aureus Bacteremia or Endocarditis: A Systematic Review and Meta-Analysis of Randomized, Controlled Trials.Clin Infect Dis 80, no. 1 (February 5, 2025): 29–36. https://doi.org/10.1093/cid/ciae476.
Mourad, Ahmad, et al. “Oral Versus Intravenous Antibiotic Therapy for Staphylococcus aureus Bacteremia or Endocarditis: A Systematic Review and Meta-Analysis of Randomized, Controlled Trials.Clin Infect Dis, vol. 80, no. 1, Feb. 2025, pp. 29–36. Pubmed, doi:10.1093/cid/ciae476.
Journal cover image

Published In

Clin Infect Dis

DOI

EISSN

1537-6591

Publication Date

February 5, 2025

Volume

80

Issue

1

Start / End Page

29 / 36

Location

United States

Related Subject Headings

  • Treatment Outcome
  • Staphylococcus aureus
  • Staphylococcal Infections
  • Randomized Controlled Trials as Topic
  • Microbiology
  • Humans
  • Endocarditis, Bacterial
  • Bacteremia
  • Anti-Bacterial Agents
  • Administration, Oral